Marble Harbor Investment Counsel LLC increased its stake in shares of Core Laboratories N.V. (NYSE:CLB) by 9.4% during the second quarter, according to its most recent filing with the SEC. The fund owned 10,466 shares of the oil and gas company’s stock after buying an additional 900 shares during the period. Marble Harbor Investment Counsel LLC’s holdings in Core Laboratories N.V. were worth $1,060,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Core Laboratories N.V. by 0.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,977 shares of the oil and gas company’s stock valued at $1,112,000 after buying an additional 98 shares during the period. Monroe Bank & Trust MI boosted its stake in shares of Core Laboratories N.V. by 1.4% in the second quarter. Monroe Bank & Trust MI now owns 9,185 shares of the oil and gas company’s stock valued at $930,000 after buying an additional 130 shares during the period. Neuberger Berman Group LLC boosted its stake in shares of Core Laboratories N.V. by 6,220.7% in the second quarter. Neuberger Berman Group LLC now owns 251,313 shares of the oil and gas company’s stock valued at $25,450,000 after buying an additional 247,337 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of Core Laboratories N.V. by 27.4% in the second quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 19,245 shares of the oil and gas company’s stock valued at $1,949,000 after buying an additional 4,140 shares during the period. Finally, Airain ltd bought a new stake in shares of Core Laboratories N.V. during the second quarter valued at about $235,000.

Shares of Core Laboratories N.V. (NYSE CLB) traded up 0.30% during trading on Thursday, reaching $87.73. The company had a trading volume of 37,039 shares. The firm has a market capitalization of $3.87 billion, a PE ratio of 53.82 and a beta of 1.60. Core Laboratories N.V. has a 1-year low of $87.27 and a 1-year high of $125.83. The firm has a 50-day moving average of $98.61 and a 200 day moving average of $106.75.

Core Laboratories N.V. (NYSE:CLB) last posted its quarterly earnings results on Monday, July 24th. The oil and gas company reported $0.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.01. Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. The business had revenue of $163.90 million during the quarter, compared to analyst estimates of $168.23 million. During the same period in the previous year, the business posted $0.35 EPS. The company’s quarterly revenue was up 10.7% on a year-over-year basis. Analysts expect that Core Laboratories N.V. will post $2.09 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Monday, August 14th. Stockholders of record on Monday, July 17th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.52%. The ex-dividend date was Thursday, July 13th. Core Laboratories N.V.’s dividend payout ratio (DPR) is presently 134.15%.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/marble-harbor-investment-counsel-llc-buys-900-shares-of-core-laboratories-n-v-clb/1534184.html.

Several brokerages have issued reports on CLB. Credit Suisse Group raised Core Laboratories N.V. from a “neutral” rating to an “outperform” rating and set a $110.00 target price on the stock in a research report on Thursday, August 24th. They noted that the move was a valuation call. BidaskClub lowered Core Laboratories N.V. from a “sell” rating to a “strong sell” rating in a report on Monday, August 14th. Morgan Stanley decreased their price objective on Core Laboratories N.V. from $130.00 to $125.00 and set an “overweight” rating for the company in a report on Monday, August 7th. ValuEngine upgraded Core Laboratories N.V. from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Finally, Citigroup Inc. decreased their price objective on Core Laboratories N.V. from $102.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $116.75.

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.